arrow
J

Javier Hernández-Losa

vall d'hebron institut de recerca
H指数:40
被引数:5,248

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multicentre validation of BRCAura, an AI-based histology model predicting germline BRCA1/2 mutations in HR+/HER2− breast cancer

基于多中心验证的BRCAura模型:一种基于人工智能的预测HR+/HER2−乳腺癌中胚系BRCA1/2突变的组织学模型

2026-10-120
OAAI
Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Genomic features, Association with Neurofibromatosis Type 1, and Progression to Rhabdomyosarcoma.

炎性横纹肌样肿瘤:临床病理及基因组特征,与1型神经纤维瘤病的关联以及进展为横纹肌肉瘤。

2026-09-260
OAAI
p38α orchestrates BRAFV600E-melanoma progression and immunotherapy response via tumor fitness and immune microenvironment modulation

p38α通过调节肿瘤适应性及免疫微环境调控BRAFV600E-黑色素瘤的进展和免疫治疗反应

2026-09-220
OA
Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer

针对转移性前列腺癌中同源重组修复基因突变优化肿瘤和生殖系检测的专家实用建议

2026-07-010
OAAI
Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer

25,946例非小细胞肺癌患者中NTRK融合的流行率及特征

2026-06-280
PRE
DNA Methylation Dynamics and Prognostic Implications in Metastatic Differentiated Thyroid Cancer
THYROID
IF6.7
2025-03-010
PRE
DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy

DSTYK抑制增强了非小细胞肺癌对紫杉烷类化疗的敏感性

2024-11-010
PRE
Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomic and transcriptomic evolution

循环肿瘤细胞外囊泡监测转移性前列腺癌基因组和转录组进化

2023-04-040
PRE
BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy

代谢应激激活BRAF促进糖酵解使NRASQ61-mutated黑色素瘤对靶向治疗敏感

2022-11-197
OAAI
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (September, 10.1038/s41467-022-32828-6, 2022)

高p16表达和杂合RB1丢失是ER乳腺癌中CDK4/6抑制剂抗性的生物标志物 (9月,10.1038/s41467-022-32828-6,2022)

2022-11-140
OAAI
Myosin Vb as a tumor suppressor gene in intestinal cancer
2022-11-011
PRE
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

高p16表达和杂合RB1缺失是ER乳腺癌中CDK4/6抑制剂耐药的生物标志物

2022-09-0747
OAAI